AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...

Cerulean Ventures, a climate tech venture capital firm in Santa Barbara, Calif,, closed a $10 million pre-seed fund to work ...

A nasal spray flu vaccine for people up to 49 will be available for home use starting in the fall of 2025 after the Food and ...

AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...

Board members from the European Central Bank are set to speak through the week, with Frank Elderson and Piero Cipollone ...

The AJ is delighted to announce the finalists of this year’s AJ Architecture Awards. The first to be revealed are in the ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

Diljit Dosanjh was joined by Ed Sheeran while he performed at Birmingham, Paris and their collab was called as the ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

It’s goodbye needles as you can keep the flu away with a nasal spray as the US Food and Drug Administration (FDA) has approved AstraZeneca’s FluMist for home use. It can be self-administered by adults ...